Save up -80% on Canakinumab
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Ilaris
|price without discount in nearest pharmacy. Price may vary.|
We offer free Canakinumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Canakinumab every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Canakinumab volume of distribution
* 6.01 L[typical CAPS patient weighing 70 kg]
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Canakinumab
Canakinumab is a recombinant, human anti-human-IL-1 monoclonal antibody that belongs to the IgG1/ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1 and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Canakinumab mechanism of action
In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1 ) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1 , and mutations in cryopyrin’s gene, NLRP-3, up-regulate IL-1 activation. Canakinumab is a human monoclonal anti-human IL-1 antibody of the IgG1/ isotype. Canakinumab binds to human IL-1 and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1 or IL-1 receptor antagonist (IL-1ra).
Dosage forms of Canakinumab
|Injection, powder, lyophilized, for solution||subcutaneous||150 mg/mL|
|Powder and solvent for solution for injection||Subcutaneous use||150 mg|
|Powder for solution||subcutaneous||150 mg|
Novartis Pharmaceuticals Canada Inc
Humans and other mammals
Indication of Canakinumab
Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
Toxicity of Canakinumab
The most common adverse reactions involved the central nervous system (headache and vertigo), gastrointestinal system (diarrhea and nausea), neuromuscular and skeletal system (musculoskeletal pain), and respiratory system (rhinitis, nasopharyngitis and bronchitis). Influenza was also reported.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Canakinumab on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.